In chronic myelogenous leukemia (CML), blocking NF-κB signals with IRAK-4 inhibition and BCR-ABL inhibition has been found to eliminate mouse and human CML leukemic stem/progenitor cells (97). This evidence concerns the gene NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive.